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Abstract 
The protein ribonucleotide reductase catalyses the de novo synthesis of deoxyribonucleotides 
(dNTPs) from ribonucleotides (NTPs), using radical chemistry. It is under strict allosteric 
regulation, partly from the dNTPs it synthesises that regulate what substrate should be synthesised, 
but also from dATP/ATP, which regulates overall activity. It is a protein that is found in almost 
every living organism and it has been subdivided in to three main classes: class I is strictly aerobic, 
class II indifferent to the presence of oxygen and class III is anaerobic. They all share a similar fold 
and reaction mechanism and most of them, with the exception of class II, require two different sets 
of homodimers to function: one generating the radical, the other carrying out the synthesis.  
This project continues previous work on the class III ribonucleotide reductase from Thermotoga 
maritima (tmNrdD), a thermophile first discovered in the vicinity of sea vents off the coast of Italy. 
The protein was expressed in Escherichia coli, purified and the purification optimised. 
Crystallisation was carried out and optimised for substrate and effector binding. X-ray diffraction 
data were collected to obtain structures of the various effector substrate complexes, to study their 
differences in structure for further insight into the protein’s allosteric substrate specificity 
regulation.  
tmNrdD was successfully purified and several structures with effector, as well as with effector 
and substrate, were obtained. The effector-substrate complex dATP-CTP bound in accordance with 
structures of the same effector substrate complex from class II, while the substrate of the dTTP-GTP 
complex was seen to bind in a previously unknown position. Here the phosphates had shifted, in 
comparison to CTP, and the ribose had flipped, pointing away from important catalytic residues. 
Substrate binding with ATP was attempted, but it was only possible to see the presence of 
pyrophosphate in the active site. Taken together with the unusual conformation of GTP this hints at 
a mobile substrate, possibly due to the protein being crystallised in an inactive state.  
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Introduction 
The first life forms on earth were strictly anaerobic and their genetic material was based on RNA 
(Robertson and Joyce 2012). However, since RNA is not so stable and prone to mutations, life 
evolved into using the reduced and more stable form of RNA, DNA, as the basis for its genetic 
material (Nordlund and Reichard 2006). Part of this evolutionary process involved developing a 
new enzyme, capable of reducing the building blocks of RNA, ribonucleotides (NTPs), into the 
building blocks for DNA, deoxyribonucleotides (dNTPs). This protein, which is the only enzyme to 
catalyse the de novo synthesis of dNTPs known to date, was ribonucleotide reductase (RNR) 
(Jordan and Reichard 1998).  
This class of enzymes was first discovered in Escherichia coli in 1961 by Peter Reichard 
(Reichard et al. 1961) and have since then been found in almost every type of living organism. The 
exceptions are a few parasites, including Giardia lamblia and Tritrichomonas foetus, which rely on 
their hosts and salvage pathways for dNTPs (Adam 2001). RNR hydrolyses NTPs or NDPs into 
dNTPs/dNDPs using complex free radical chemistry with a thiyl radical at the active site. To 
maintain balanced dNTP pools RNR is strictly allosterically regulated at a site called the specificity 
site by the dNTPs themselves, since the same enzyme catalyses the reduction of all four NTPs. In 
addition, some RNRs also have an ATP cone, called the activity site, that binds ATP or dATP and 
regulates the overall activity of the protein: ATP activates and dATP deactivates it (Nordlund and 
Reichard 2006).  
The RNRs have been subject to much divergent evolution and are today divided into three 
classes, based on how they interact with oxygen and how they generate their radical (Torrents et al. 
2001; Larsson et al. 2004). Evolution is assumed to be divergent, and not convergent, primarily 
because of the very high similarity in allosteric regulation between the different classes (Poole et al. 
2002) and their common overall structure (Nordlund and Reichard 2006). The three classes share 
structural similarities, even if their sequence identity can be very low. From an evolutionary 
perspective it is commonly agreed that class I is the newest form of the enzyme: it is strictly 
aerobic, unlike the other two classes, and would have evolved after the appearance of oxygen, while 
DNA, and thus RNR, evolved before this. Class III is generally considered to have been the first 
type of RNR. However, the matter is still under some debate (Torrents et al. 2002) and there is a 
possibility class II might instead have been first (Poole et al. 2002). 
 
Class I 
Class I is, as already mentioned, strictly aerobic and is split into the subgroups Ia, Ib and Ic. It is the 
most studied and the most widespread: Ia can be found in all higher organisms, as well as many 
microorganisms, while Ib is only found in bacteria (Johansson et al. 2010) and Ic mostly in 
parasites (Hogbom 2011). It normally consists of two homodimeric proteins: α2 and the smaller β2 
(Rofougaran et al. 2006). While α2 contains the active, activity and specificity sites, β2 contains an 
Fe-O-Fe centre used to generate a tyrosyl radical. This radical is then transferred to a cysteine at the 
active site on the α subunit, generating the thiyl radical required for the enzyme to function. Ic 
instead uses an Mn-Fe centre for radical generation and storage, lacking the otherwise strictly 
conserved tyrosine entirely (Hogbom 2011). The electrons required for the reduction of the NTPs 
are supplied by thioredoxin for class Ia, and the additional protein NrdH for class Ib (Jordan et al. 
1997). All class Ia and some Ib enzymes contain the ATP cone activity site on the α2 protein. For 
mice it has been shown that when ATP or dATP binds to hyperactivate or deactivate the protein, 
respectively, class I proteins enter a higher oligomeric state, forming α6β2 oligomers, instead of the 
normal α2β2 complex (Rofougaran et al. 2006). In E. coli the RNR instead forms the α2β2 complex 
when active, and an α4β4 complex when inhibited by dATP (Rofougaran et al. 2008).  
 
Class II 
Class II RNRs are indifferent to oxygen and can be found in prokaryotes. They lack the β2 protein, 
existing as homodimers or monomers of the α subunit. Those that are monomeric contain an 
additional 130 residue insertion to mimic the dimer interface (Sintchak et al. 2002), which is 
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important for allosteric regulation. Since class II lacks the β2 protein, which normally generates the 
radical required for enzymatic activity, they instead use the additional cofactor adenosylcobalamin 
to create a transient 5’-deoxyadenosyl radical, which it transfers to the α subunit to give the same 
active site thiyl radical as for class I (Larsson et al. 2004). They use thio- or glutaredoxin as electron 
donors (Nordlund and Reichard 2006). 
 
Class III 
Class III is present only in prokaryotes and is strictly anaerobic. It initially generates a stable glycyl 
radical, being one of only four enzymes with known structure that use them (Luttringer et al. 2009). 
If the active glycyl radical is exposed to oxygen a cleavage occurs adjacent to it, removing the 25 
C-terminal residues, including the radical itself and rendering the protein non-functional (King and 
Reichard 1995). Though class III requires an α2 and a β2 protein, the latter only functions as an 
activase. This activase generates the glycyl radical on α2 by cleaving S-adenosylmethionine with the 
help of an Fe-S cluster, generating an adenosyl radical, which is transferred to the glycine. The 
generated glycyl radical is then stable for several cycles of catalysis, and so the activase dissociates. 
This radical is presumably shuttled between the glycine, where it is stored, and the active site 
cysteine, where it enables NTP reduction (Logan et al. 1999). α2 uses formate as the electron donor 
in the catalysed reaction (Mulliez et al. 1995). Class III RNRs contain an additional metal site not 
found in the other classes: a Zn site co-ordinated by 4 cysteines, or sometimes 3 cysteines and a 
histidine, containing one Zn, in the C-terminal region. This metal site is believed to assist in 
interactions with the β2 protein, meaning it is indirectly important for enzymatic activity (Logan et 
al. 2003).  
 
Overall structure 
The first RNR structure to be solved was the Class I enzyme in 
E. coli (Nordlund and Eklund 1993; Uhlin and Eklund 1994) 
and since then structures from every class have been solved, 
with the exception of the β2 protein from class III. All three 
classes share important structural features and a common overall 
fold of the α subunit, which consists of a 10-stranded α/β barrel 
with two sets of five parallel β-sheets, arranged in an antiparallel 
manner. A connecting finger loop protrudes into the cavity 
created in the centre (Uhlin and Eklund 1994; Logan et al. 1999; 
Sintchak et al. 2002). At the tip of this loop the cysteine 
harbouring the thiyl radical is located, meaning this region 
contains the active site. The specificity site is instead located by 
the interface of the α2 dimer and a loop, commonly referred to as 
loop 2, connects it with the active site. The activity site, present 
in only some RNRs, is located far from either of these sites, 
being situated in the N-terminal region of the protein in a small α-helical bundle (Figure 1) 
(Nordlund and Reichard 2006).  
In this setup the interactions of the dimers plays an important part, since the specificity site 
consists of residues from both subunits. It is for this reason that monomeric class II RNRs contain a 
region mimicking the dimer interface. Dimeric class II are organised in a similar way to class I. The 
α subunits of class III, however, dimerise with the β-barrel pointing at a 90° angle compared to 
classes I and II, making the distance between the active and specificity sites longer. Despite this 
loop 2 still bridges the distance between the 2 sites (Figure 2) (Nordlund and Reichard 2006).  
 
Figure 1 The general structure of an 
RNR (Logan 2011). 
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Figure 2 Overview of the three classes of RNR, showing how the dimers are oriented. 
The ATP-cone is blue, the binding site for adenosylcobalamine is brown. Loop 2 and 
bound dNTP are coloured red. Abbreviations used: L2 = Loop 2, S = Specificity site 
and A = Activity site. From: (Nordlund and Reichard 2006) 
 
Reduction mechanism 
The reduction of NTP/NDPs by RNR is similar in all three classes, though class III differs the most. 
Class I use diphosphates as substrates, class III use triphosphates and in class II there are examples 
of both being used (Kolberg et al. 2004). The stable tyrosyl radical on the β2 protein in class I, or the 
transient adenosyl radical generated by adenosylcobalamin for class II, are transferred to a 
universally conserved cysteine at the tip of the finger loop, at the active site of the α2 protein. This 
cysteine, corresponding to Cys439 in Class I Escherichia coli RNR, creates a transient thiyl radical 
(Reece et al. 2006). When an NTP binds, the ribose is positioned so that the thiyl radical cysteine is 
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close to the 3´-carbon, from which it removes the hydrogen atom and creates a substrate radical 
intermediate. The radical is then moved, through the 2´C and O to Cys225. This removes the 
oxygen atom, which becomes protonated and leaves as water. The 2´C is reprotonated again by the 
sulphide on Cys462, which creates a disulphide bridge with Cys225 and the two become a 
disulphide radical. This radical is transferred back the 3´C of the ribose, causing the reverse of the 
initial reaction step: the 3´C is protonated and the Cys439 thiyl radical is regenerated. From here it 
is transferred back to the cysteine on the α2 protein where it was generated, where it is stable 
enough to await the next round of catalysis. The disulphide bond formed between Cys225 and 
Cys462 is regenerated using thio- or glutaredoxin (Nordlund and Reichard 2006). Cys225 and 
Cys462 are generally conserved and located on 2 adjacent barrel β-strands in the active site (Logan 
et al. 1999).  
The crystal structure of a class III RNR with bound substrate is yet to be published, but a 
reduction mechanism has still been suggested. The stable glycyl radical (Gly580, Bacteriophage T4 
(BT4)) is located on the α2 protein, instead of β2, and is brought into contact with the active site 
cysteine (Cys290, BT4 numbering, corresponds to Cys439 in E. coli) through a long loop from the 
C-terminal region (Andersson et al. 2000). The initial and final steps of the reduction are similar to 
that of class I and II. However, only Cys225 is conserved in class III (Cys79, BT4 numbering), 
there is no Cys462 equivalent, and since there is only one cysteine no disulphide bridge is formed. 
Cys79 still harbours the radical intermediate and the reduction and generation of water is instead 
performed by formate, which binds directly at the active site. After one round of reduction the 
radical is transferred back to Gly580, similarly to what happens in class I (Figure 3) (Eklund and 
Fontecave 1999).  
 
Figure 3 Proposed reduction mechanism of the class III RNR. The residues are numbered according to                 
BT4 class III RNR (Andersson et al. 2001).  
 
Allosteric regulation  
RNR is allosterically regulated at the specificity and activity sites. The specificity site on the α 
subunit regulates the production of different dNTPs: binding dTTP stimulates reduction of GTP. 
Production of the pyrimidines dUTP (later converted to dTTP by a thymidylate synthase) and dCTP 
are upregulated by dATP and ATP. dGTP binding stimulates dATP reduction (Figure 4) (Kolberg et 
al. 2004). All four dNTPs that regulate RNR bind in a similar manner at the dimer interface: for 
class I and II the phosphate is anchored in one monomer, being neutralised by a lysine and an 
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arginine. The 3´OH of the deoxyribose binds directly to an aspartate, and a glycine through a water 
molecule, with the base sticking out towards loop 2 on the other monomer (Figure 5 and 6) (Larsson 
et al. 2004). While the effector binds across the dimes interface axis for classes I and II, it instead 
binds along the dimer interface axis in the class III RNRs 
(Larsson et al. 2001).  
Each base affects the conformation of loop 2 differently, in 
turn affecting the specificity of the active site. In class I and II this 
is primarily dependant on three amino acid residues: Lys202, 
Gln203 and Arg207 (Thermotoga maritima class II RNR 
numbering). When dTTP-GDP is bound loop 2 adopts a β-hairpin 
structure, making 4 hydrogen bonds to dTTP. One is direct, by 
Lys202 to the CO (O4) of the base, and three are bridged by 
water: the carbonyl of Gln203 and the amide nitrogen of Gly204 
to CO (O4), and the carbonyl on Val200 to N3 (Figure 5). The 
conformation of loop 2 gives space for GDP, which is very bulky, 
in the active site and  
projects Arg207 into the 
binding pocket, clam-
ping the substrate down into it. Here the adenosine 
guanidinyl moiety makes π-π  stacking interactions with 
the base and water bridges the residue with the ribose and 
phosphates of the substrate. Interestingly, when no 
substrate is bound, dTTP does not hydrogen bond with 
loop 2, indicating that the substrate is also required to 
stabilise this conformation (Table 1 and Figure 6) 
(Larsson et al. 2004).  
Loop 2 also forms a β-hairpin when binding dATP-
CDP/UDP, but it is truncated with increased regions of 
disorder. This is stabilised by NH (N6) and N1 in dATP, 
which hydrogen bond to the backbone carbonyl and amide 
groups of Lys202, respectively. Loop 2 also binds 
CDP/UDP: Gln203 projects into the active site, hydrogen 
bonding with the NH and CO groups of the CDP base, but only to CO for UDP (Table 1, Figure 5) 
(Larsson et al. 2004).  
 For dGTP/ADP loop 2 is disordered, with the exception of an additional turn at the end of the helix 
that it is attached to, and an α-conformation of residues 201-203. Val200 and Val201 hydrogen bond 
to the NH (N2) and NH (N3) of dGTP to stabilise this. Lys202 is projected into the active site, 
hydrogen bonding to the N1 atom on the ADP base (Table 1, Figure 5 and 6) (Larsson et al. 2004).  
For class III there are only structures with bound effector. Here the phosphate and ribose of all 
dNTPs interact with the same residues. The phosphates are co-ordinated by a Mg ion and interact 
with several lysines, as well as Gln176 (BT4 class III numbering), while the 3´-OH of the ribose 
hydrogen bonds to Glu100. The two main residues responsible for effector recognition are Gln114 
and Glu181. Gln114 hydrogen bonds to N1 for dATP, N3 and O4 in dTTP and N3 and N4 in dCTP. 
dGTP does not interact directly with Gln114, but this residue is part of a hydrogen bonding network 
that includes Glu181 and dGTP. Glu181 hydrogen bonds to N6 in dATP and N1 and N2 in dGTP, 
but does not directly interact with dTTP or dCTP, instead hydrogen bonding with Gln114 in those 
cases. Loop 2 retains the conformation of the native state when dATP is bound and undergoes the 
largest changes when affected by dTTP (Larsson et al. 2001).  
The activity site is generally found in class Ia and several class III RNRs (Logan 2011). It 
requires higher levels of ATP/dATP, since they otherwise only associate to the active and effector 
sites, respectively (Nordlund and Reichard 2006). The activity site allows regulation of overall 
dNTP levels, important since too high levels may increase the mutation rate (Chabes et al. 2003). 
Figure 4 Overview of the allosteric 
regulation of RNR. (Larsson et al. 2001) 
Figure 5 The four different nucleotides, here shown 
as monophosphates. The ribose and base rings are 
numbered. 
(www.tulane.edu/~biochem/nolan/lectures/rna/frames/nucs.htm)  
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Table 1 Overview of the different interactions between RNR and its substrates and effectors. T. maritima class II 
RNR numbering. For numbering of the atoms in the effector, see figure 5. 
      Regions that bind from: RNR Residues that bind to:  
Effector Substrate Loop 2 conformation Effector Substrate Effector Substrate 
   dTTP GDP β-hairpin CO (O4), N3 
π-π stacking 
interactions 
from the base 
Val200, Lys202, 
Gln203, Gly204 
Arg207 
dGTP ADP 
Disordered, except a turn at the 
end of helix αB and α-conformation 
of residues 201-203. 
NH (N2), NH 
(N3) 
N1 Val200, Val201 Lys202 
dATP 
CDP Truncated β-hairpin with increased 
regions of disorder 
NH (N6), N1 
NH, CO 
Lys202 Gln203 
UDP CO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Specificity site structure for tmNrdJ, a class II RNR from T. maritima, showing 
the different effectors bound with and without substrate. Some constant interactions to the 
ribose have been omitted for clarity (Larsson et al. 2004).  
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The studied class III enzymes 
The presence of a third, anaerobic class of RNRs was first found in cell extracts from 
Methanobacterium thermoautrophicum (Hogenkamp et al. 1987). Since then the class III RNRs 
have been primarily studied in E. coli (Fontecave et al. 1989), BT4 (Young et al. 1994) and, to a 
somewhat lesser extent, Lactococcus lactis (Torrents et al. 2000) and T. maritima (Aurelius 2011). 
The latter is an anaerobic eubacteria, which can be found by sea vents on the ocean floor round Italy 
and the Azores (Huber et al. 1986). The first class III enzyme to be structurally solved and 
characterised was from BT4 (Logan et al. 1999). Since then only the structure of the T. maritima 
class III RNR has also been solved (Aurelius 2011). The three RNRs from L. lactis, E. coli and BT4 
share about 50% sequence identity, while T. maritima only has about 30-25% sequence identity 
with these three.  
 
Homologues to class III RNR 
The class III RNR activases are part of the radical S-adenosylmethionine (SAM) superfamily and 
here several homologues can be found. These proteins all use SAM to generate an adenosyl radical, 
most commonly for cleaving C-H bonds. A common motif, CxxxCxxC, together with SAM, binds 
four irons to create a 4Fe-4S cluster which catalyses the reaction, present in β2 for class III RNR. 
While SAM is mostly used only as a coenzyme and regenerated after each round of catalysis, class 
III RNRs are part of a group which actually use it as a substrate. Examples are biotin synthase and 
lipoyl synthase, which use SAM to insert a sulphur into a C-H bond. Class III RNR, pyruvate 
formate lyase 1 (PFL, along with pyruvate formate lyase 1 activating enzyme), benzylsuccinate 
synthase and glycerol dehydratase use SAM for the generation of a glycyl radical. Of these, PFL 
was the first enzyme to be discovered to use glycyl radicals (Wang and Frey 2007). PFL and its 
activase are the ones most commonly mentioned as homologues to class III RNR’s α2 and β2, 
respectively (Torrents et al. 2001). The two proteins are thought to have a common origin and are 
both anaerobic, PFL being a part of anaerobic metabolism (Poole et al. 2002).  
 
Previous and current work 
This project focused on purification and structural studies of the α2-subunit of class III RNR from T. 
maritima (tmNrdD) using X-ray crystallography, which has already been studied within the group. 
All purification and initial preparation of tmNrdD was done by Etienne Mulliez in Grenoble. He 
also produced Se-Met versions of the protein to assist in solving the phase problem. The initial 
crystallisation screens were done by Alexander Balhuizen and Renzo Johansson, focusing on a 
different crystal form to the current one. Tobias Beck set up commercial crystallisation screens and 
one possible hit from these was followed up by Oskar Aurelius, producing the current crystal form 
in citrate buffer. He also produced Se-Met crystals for multiple wavelength anomalous dispersion 
data collection and phase determination, solved the structure and collected some datasets of dNTP-
RNR complexes, produced mostly by soaking. Renzo Johanson later collected a data set on a native 
crystal in 2-(N-morpholino)-ethanesulfonic acid (MES) buffer and did some surface plasmon 
resonance trials to see if the substrate interacts with tmNrdD.  
The current project focused on determining the difference in structure of the protein tmNrdD 
while bound to its various effectors and substrates. To facilitate this, production and purification of 
tmNrdD was carried out, based on a protocol from Etienne Mulliez. The protein has a confirmed 
metal site, which in E. coli and BT4 is known to contain Zn (Logan et al. 2003; Luttringer et al. 
2009). It also co-binds Mg with the effector to coordinate the phosphates and the exact position of 
this metal ion in tmNrdD had not been confirmed. Thus, metal characterisation of these two sites 
was carried out, substituting Mg for Mn. The protein was crystallised in MES buffer and 
crystallisation optimised in the new conditions. The produced crystals were used to do the metal 
characterisation and to study the difference in structure with bound effectors and substrates through 
X-ray crystallography.  
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Methods 
Protein purification 
pRSFduet-1 plasmids containing the tmNrdD gene were transformed into chemocompetent cells 
from the E. coli strain BL21-CodonPlus(DE3)-RIL (Agilent Technologies) using heat shock at 42°C 
for 30 s. The transformants were stored as glycerol stocks at -80°C, which were used for all 
subsequent cultures. Some of these cells were streaked on to agar plates and single colonies 
inoculated in 10 ml LB-medium overnight at 37°C. These 10 ml were used to inoculate 1 l of LB-
medium, which was grown at 37°C to an OD600 of 0.5-0.7. Protein expression was induced by 
adding IPTG to a final concentration of 250 μM, and the culture continued for 3 hours. The cells 
were harvested by centrifugation at 6000 rpm for 12 min. All growth media contained ZnCl2 (150 
μM), chloramphenicol (100 μg/ml) and kanamycin (30 μg/ml), the agar plates contained kanamycin 
and chloramphenicol to the same concentrations.  
The amount of time necessary to reach optimal protein expression was investigated by growing 
the cultures for 5 hours after the addition of IPTG. 1 ml was removed at regular time intervals and 
used to measure OD600, as well as for running on an SDS-PAGE gel. The presence of the 
contaminant chloramphenicol acetyl transferase (CAT) was used as a guide to determine relative 
concentrations of the samples on the gel, and the amount of protein in each relevant band analysed 
to determine optimal growth time. The intensities of the bands on the gel were analysed with the 
ImageQuant TL software (GE Healthcare). To determine whether CAT, the chloramphenicol 
resistance protein, affected growth or expression, cultures were grown in the presence of 
kanamycin, but without chloramphenicol. The CAT gene is only important for the RIL plasmid and 
not essential to maintain the tmNrdD plasmid in the cells. The difference in growth was compared 
through their OD600 measurements and by running both types of culture on an SDS-PAGE gel.  
The cell pellets were dissolved in about 25 ml lysis buffer (50 mM TrisHCl, 250 mM KCl, 200 
μM PMSF, 5 mM dithiothretiol (DTT), pH 8) and the cells were lysed using a French press. The 
cell debris were removed by centrifugation at 20 000g for 20 minutes and the pellet saved as P1. 
Since tmNrdD is thermophilic, contaminating proteins were removed by heating the supernatant to 
75°C for 5 minutes. This incubation was initially performed for 20 min, but to minimise the loss of 
protein the time was reduced. The sample was centrifuged (10 000 g, 10 min, pellet saved as P2), 
before the supernatant was saturated with 60% ground ammonium sulphate, to precipitate the 
remaining protein, including tmNrdD. This was centrifuged at 10 000 g, 10 min, the supernatant 
saved as S1 and the pellet saved at -20°C as P3. To further optimise the purification protocol it was 
investigated weather sonication improved the protein yield compared to French press. The dissolved 
cell pellets were sonicated at 45 W with 20 s pulses and 60 s rest, run for 6 cycles.  
The P3 pellet was dissolved in Buffer I (1M ammonium sulphate, 50 mM TRISHCl, 50 mM 
KCl, pH 8) and the concentrations of protein and nucleotide were measured with Nanodrop 
(Thermo Scientific) before it was centrifuged at 10 000 g for 10 min. The supernatant was run on a 
Butyl Sepharose high trap FF column, 5 ml (GE Healthcare), where it was eluted with a gradient 
from 0%-100% Buffer II (50 mM TrisHCl, 50 mM KCl, pH 8) at a flow rate of 5 ml/min. All 
fractions from the appropriate protein peak were pooled. After measuring protein concentration the 
samples were concentrated in 15 ml concentration tubes with a molecular weight cutoff of 30 kDa 
(Millipore centrifugal filters). As a final step the tube was filled with elution buffer (5 mM DTT, 50 
mM TrisHCl, 50 mM KCl, pH 8), concentrated to the desired volume and the concentration 
measured again. An SDS-PAGE gel and mass spectrometry (MS, method described below) were run 
on the concentrated fractions. The protein was transferred to a different tube and stored at 4°C.  
As a final step the concentrated protein was run with the elution buffer on a 23 ml Superdex 200 
column (GE Healthcare), with a flow rate of about 0.5 ml/min. TmNrdD appeared as a large peak at 
about 10 ml after addition of the concentrate and fractions were collected and pooled in this area. 
The concentration of the pooled fractions was measured, they were concentrated to about 25 mg/ml 
and dynamic light scattering (DLS) was used to check homogeneity. The protein was aliquoted into 
20-30 μl portions, flash frozen in liquid nitrogen and stored at -80°C for later use.  
A detailed protocol for the purification can be found in appendix I.  
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NMR and Mass spectrometry 
To investigate the binding of tmNrdD to its effectors and substrates it was analysed with nuclear 
magnetic resonance spectrometry (NMR), together with various nucleotides. Solutions of protein in 
D2O were run with 100 μM effectors and 50 μM substrate in 20 mM TrisHCl, 50 mM NaCl, 2 mM 
DTT, 1 mM MgCl2, at 25°C and 50°C. Proton 1D NMR experiments were conducted using a Varian 
DirectDrive 600 MHz (14.1 T) spectrometer. Water suppression was achieved by pre-saturation and 
WATERGATE methods. After an initial run the sample was incubated in the NMR tube for varying 
concentrations of NrdD up to 12 μM, to observe a possible shift change or broadening of the peaks 
for the hydrogens of C1 and C5 for the pyrimidines and C8 for the purines (figure 5), which would 
be indicative of binding. Two different batches of protein were used. Both batches, NrdD1 and 
NrdD2, were sent by Etienne Mulliez, and were purified using similar protocols to the one 
described above, but using sonication to lyse the cells instead of French press. NrdD1 was sent in 
spring 2009 and NrdD2 in spring 2012 and arrived in 50 mM TrisHCl, 50 mM KCl, 5 mM DTT, 
pH 8.0. NrdD2 was mostly used for the NMR experiments, and the different nucleotides run with it 
were dTTP, dATP, ATP, GTP, GDP or CTP in different runs and combined in presumed 
effector/substrate pairs. For NrdD1 it was instead dATP, ATP or dGTP.   
To test protein stability the NMR samples were run on an SDS-PAGE gel, along with proteins 
left in the fridge for several weeks. In-gel trypsin digestion was performed on appropriate bands 
from these gels and analysed using matrix-assisted laser desorption ionisation – time of flight / time 
of flight MS (MALDI-TOF/TOF MS). For the in-gel digestion the bands were cut out of the gel and 
washed with 50 mM NH4HCO3 50% ethanol (v/v) until the gel pieces were no longer blue. They 
were then dehydrated in 50% ethanol (v/v) for a few minutes until white and opaque, before 
reduction by incubation at 37°C for 30 min in 10 mM DTT 50 mM NH4HCO3. After another 
dehydration step they were alkylated with 10 μl 0.55 mM iodoacetamide in 50 mM NH4HCO3 in 
the dark for 30 min. The gel was washed with 50 mM NH4HCO3 50% ethanol (v/v) for five minutes 
and then dehydrated again. The liquid was removed, the gel pieces dried and digested with 8 μl 12 
ng/μl trypsin in 50 mM NH4HCO3 for five minutes. Excess liquid was removed before 8 μl 50 mM 
NH4HCO3 was added and the gel pieces incubated at 37° over night. 8 μl 0.5% TFA was used to 
extract the peptides by incubation for 30 min at room temperature, before spotting on a MALDI 
plate. A MALDI matrix solution consisting of 5mg/ml hydroxycinnamic acid in 50% acetonitrile, 
0.1% (v/v) phosphoric acid (Kjellström and Jensen 2004), was added afterwards to each position. 
The Matrix solution contained two peptide standards [des-arg-bradykinin (m/z 904.468) and ACTH 
18-39 (m/z 2465.199)] that were used for internal mass calibration in every analyte/matrix position. 
MALDI-MS and MS/MS analyses of the fractions were performed on a 4700 Proteomics Analyzer 
MALDI-TOF/TOF™ mass spectrometer (Applied Biosystems, Framingham, MA). MS/MS data 
acquisition was performed in a two-step process as described previously (Gonzalez et al. 2009). 
Database searching was done using Mascot (Matrix Science) with Swissprot as the database and 
with a peptide mass tolerance of 50 ppm and a fragment mass tolerance of 0.2 Da. 
 
Crystallisation 
TmNrdD, both from NrdD2 and newly produced batches, was crystallised with MES buffer, based 
on conditions that had previously been successful. Most of the initial screens were set up at the 
MAX-lab crystallisation facility. Table 2 shows a general overview of the different screens 
conducted. All screens contained, unless otherwise stated, 5 mM DTT and 100 mM MES and were 
crystallised using vapour diffusion with sitting drop in MRC plates (Jena Bioscience) or EasyXtal 
plates (Qiagen). The nucleotide screens also contained 10 mM MgCl2, except in a couple of cases 
when Mn was used instead. Mn will bind in a similar manner to Mg, allowing metal 
characterisation of that site, and was used since it has an flourescence edge wavelength that is 
possible to measure with an X-ray light source. All proteins were centrifuged for 10 min at 10 000 g 
before pipetting into the screens, to remove aggregates. The later screens used protein that had been 
dialysed with MES buffer, pH 7.5, for 20 min with slow stirring to remove the Tris it was in.  
Table 2 Overview of the different crystallisation screens performed with tmNrdD.  
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Screen [Protein] 
(mg/ml) 
Added nucleotides and other 
variables 
pH %PEG 
Original native 20 - 4.9-5.9 9-17 
Microseeding 10 and 5 - 5.7-6.1 6-12 
dNTP 10 and 5 All dNTPs 5.7-5.9 8-12 
dNTP+NTP 10 All dNTPs, GDP 5.7-5.9 10-12 
Native, larger drops 10 100 or 80 mM MES 5.7-5.9 10-12 
dNTP, heated
3
 10 All dNTPs 5.7-5.9 10-12 
Heated vs unheated
3
 10 100 or 80 MES 5.5-5.9 10-13 
Mg vs Mn 10 dTTP, 10 mM MgCl2 or MnSO4 5.7-5.9 10-12 
First new batch
1
 6.87 - 4.9-5.9 10-15 
Second batch
1
 20, 15 and 4.5 - 4.9-5.9 8-20 
Test peak 1 and 2
1
 20 - 5.3-5.9 14-20 
3
rd
 batch conc. test
1
 20, 10 and 5 - 5.3-6.3 11-22 
Higher pH
1
 20 - 5.5-6.5 10-19 
Zn and MES dialysis
1
 20 1 mM Zn or dialysed with MES 5.5-6.1 10-19 
Co-crystallisation
1
 20 All dNTPs 5.5-6.1 10-19 
Oskar’s new batch1, 2 20 - 5.5-6.5 11-19 
dNTP screen
1, 2
 20 dATP, dGTP and dCTP 5.7-6.1 12-17 
dNTP screen, heated
1, 2, 3
 20 dATP, dGTP and dCTP 5.7-6.1 12-17 
Larger drops
1, 2
 20 - 5.7-6.3 17-19 
Pipette test
1, 2
 20 By hand  5.9-6.1 14-19 
High-throughput 1
1, 2
 20 By hand, hanging drop 5.9 16-17 
High-throughput 2
1, 2
 20 By hand, hanging drop 6.1 16-17 
1
 = Used protein from batches produced as part of this project.  
2
 = The screens were performed with protein dialysed in MES-buffer for 20 min at room temperature.  
3
 = Protein and nucleotide (where applicable) were heated to 75°C for 20 min, then cooled for 1 h in the heat block 
before pipetting into the screen.  
 
Data collection 
Data collection on promising crystals was carried out at the I911-3 beamline station at MAX-lab 
with a 225 mm marMosaic CCD detector and the ID23-1 beamline at the European Synchotron 
Radiation Facility (ESRF) with a PILATUS 6M-F detector. The cryoprotectant for the older batch 
(NrdD2) contained 20% polyethylene glycol (PEG) 400, 12% PEG3000, 100 mM MES pH 5.7 and 
0.5 mM dNTPs or/and 2 mM NTPs, where applicable. For the crystals from newer batches the 
cryoprotectant was the same, except the pH was 5.9 and it also contained 5 mM DTT. Most of the 
data was collected at wavelengths around 0.9-1.0 Å. Some crystals were used for metal 
characterisation of Zn, Fe and Mn, and for these crystals the most appropriate wavelength for 
anomalous data collection of each metal was determined by fluorescence scans. For Fe a 
wavelength that was known to be on the high energy end of the theoretical absorption edge was 
used: the fluorescence scan readout was of so low intensity that an optimal wavelength could not be 
determined. The wavelengths used for the different metal characterisations were 1.28 Å for Zn, 1.89 
Å for Mn and 1.60 Å for Fe. Appendix II gives a more comprehensive overview of the crystals 
tested for data collection.  
 
Data processing, Modelling and Refinement 
Indexing, integration of the diffraction images, scaling of the data and generation of an mtz file was 
done using the XDS suite of programs (Kabsch 2010). Using data from a previously solved native 
structure (Aurelius 2011), the Rfree flags were imported using CCP4 (Winn et al. 2011), after which 
followed rigid body refinement with refmac5 through CCP4 (Murshudov et al. 2011). In a couple of 
cases the models were not solvable by rigid body refinement, in which case molecular replacement 
was done with the same native structure, using the Phaser software through CCP4 (McCoy et al. 
2007). Restrained refinement was then carried out, again with refmac5 through CCP4, before 
manual refinement in Coot (Emsley et al. 2010), with any effectors or substrates added early in the 
refinement process. Several cycles of alternating refmac5 restrained refinement and Coot manual 
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editing was then carried out to tidy up the models. The web based program MolProbity was used for 
further validation after each of the later refinement cycles (Chen et al. 2010). To evaluate effector 
and substrate binding the average B-factors, as well as B-factors of all bound phosphate groups, 
were compared.  
 
 
 
Results 
Protein purification 
OD600 was reached after roughly 3.5 h and there was no clear difference in cell yield between the 
cultures grown with or without chloramphenicol (Table 5). Chloramphenicol also did not seem to 
affect the presence of CAT. It was only necessary to continue protein expression for 3 h after 
induction, since expression plateaued after this time (Figure 7, Table 3).  
 
       1    2     3    4     5    6    7    8     9   10   11   12  13 
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              25 kDa 
 
              15 kDa  
       
 
             10 kDa 
Figure 7 SDS-PAGE gel determining optimal length of time for protein expression. Lane 1-9 are samples 
taken at the following time points, in order: at inoculation (time 0), 1 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h and       
5 h. Lane 11 is not related.  
 
Table 3 Overview of the intensity analysis of the bands in figure 7. The intensity of the bands at 70 kDa (tmNrdD) and 
25 kDa (CAT) in figure 7 were plotted graphically, and the area under the peaks used for this table. To compare the 
relative intensities of various lanes the tmNrdD peak area was first divided by the CAT peak area. These values were 
then all divided by this value for time 0 to determine the relative increase in intensity.  
Lane 1 2 3 4 5 6 7 8 9 
NrdD (intensity peak area) 1700 2900 3100 3100 3100 3700 3700 3600 3700 
CAT (intensity peak area) 3800 3000 3200 3000 3300 3300 3400 3400 3400 
NrdD/CAT 0.447 0.967 0.969 1.033 0.939 1.121 1.088 1.059 1.088 
(NrdD/CAT)/(t0(NrdD/CAT)) 1 2.161 2.165 2.310 2.100 2.506 2.433 2.367 2.433 
Time (min) 0 60 120 150 180 210 240 270 300 
 
Sonication gave a higher P1 weight than French pressing, but not enough to be significant, since 
the pellet weight between different French pressed batches varied greatly. P1 was always the 
smallest of the pellets generated during purification, weighing about 0.5 g per litre culture. Manual 
inspection of SDS-PAGE gels run when the solubilised P1 pellet was incubated for 20 min, 
compared to 5 min, showed a clear decrease in the relative intensity of the tmNrdD band (Figure 8). 
The P2 pellet was always the largest and weighed about 1.7 g per litre culture. The final pellet, 
which was precipitated with ammonium sulphate, had an average weight of 0.8 g per litre culture 
(Table 5).  
 
 
 
 
 
tmNrdD 
CAT 
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Figure 8 A comparison of the pellets from purification when the sample had been  Figure 9 The final SDS-PAGE 
heated for 20 min (A) or 5 min (B). tmNrdD is located at 70 kDa (the red band in  gel of the two butyl sepharose 
the ladder). Lanes in A (1-5, respectively): P2, P3, Ladder, S1, P1. Lanes in B (1-5 peaks. tmNrdD is 70 kDa while 
respectively): P1, P2, P3, S1, ladder.       CAT is 25 kDa. Lanes 1 and 2
          are butyl sepharose peaks 1 and
          2, respectively.  
     
Two peaks were visible at the end of the butyl Sepharose elution profiles and collected 
separately. The first peak contained predominantly tmNrdD, while the second one contained both 
tmNrdD and CAT, which was determined with MS (results not shown) and SDS-PAGE (Figure 9). 
It was possible to separate CAT and tmNrdD form the second peak with gel filtration, but the 
tmNrdD yield was so low that this peak was not used in subsequent purification batches. For the 
tmNrdD peak the gel filtration mainly showed one large peak at about 10 ml from injection (Figure 
10). The final protein yield increased by roughly a factor of two for each batch of expression, with 
the final batch reaching a yield of about 4.3 mg wet weight of protein for 1 l liquid culture (Table 
4).  
 
Table 4 Overview of protein purification, showing the weights of each cell pellet and 
the protein yield per litre of bacterial culture. All weights are the wet weight of the 
pellet.  
  Cells (g) P1 (g) P2 (g) P3 (g) Yield (mg) 
121207-1 4.44   2.32 0.49 0.34 
121207-2 4.30 0.67 3.20 1.08   
121207-3 3.48         
121207-4 2.94         
130118-1 3.61 0.53 1.98 1.02 0.80 
130118-2 3.08 0.35 1.85 0.83 0.80 
130118-3
1
 3.40 0.73 1.17 0.71 - 
130118-4
2
 3.51 0.28 1.61 0.78 2.39 
130118-5
2
 3.20 0.28 1.61 0.78 2.39 
130118-6
2
 3.61 0.28 1.61 0.78 2.39 
130228-1km
3
 3.04 0.69 1.47 0.71 4.33 
130228-2km
3
 2.62         
130228-1ch
3
 3.18         
130228-2ch
3
 3.51         
Average 3.42 0.47 1.87 0.80   
1
=Used to test different homogenisation methods  
2
= 3 l culture pooled into two tubes, so an average is shown here 
3
=Each of these pellets contained 4 l of bacterial culture and all of them have not  
    been purified yet. 
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A 
 
B 
C 
Figure 10 Chromatography spectra from the later stages of protein purification. Red: UV 260 nm, blue: UV 280 nm, 
brown: conductivity, light green: elution gradient, dark green: pressure. A: spectra from the butyl sepharose column. 
The two larger peaks after 10 ml are, first, tmNrdD (bs1) and then tmNrdD + CAT (bs2). B: gel filtration spectra of bs1, 
where tmNrdD elutes between 10 and 15 ml. C: gel filtration spectra of bs2, where CAT is the shoulder peak of the 
larger tmNrdD peak. The final two peaks in conductivity in spectra B and C are unidentified contaminants, possibly 
nucleotides.  
tmNrdD 
tmNrdD 
CAT 
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NMR and Mass Spectroscopy 
The NMR experiments did not show any nucleotide binding, but were instead indicative of 
breakdown of all nucleotides into diphosphates, except dTTP, when using the NrdD2 batch (Figure 
11). This breakdown was not detectable for NrdD1, nor for nucleotides without the presence of 
NrdD2 protein (Figure 13). The absolute shifts were around 7.7 ppm and 1.9 ppm for the C1 and C5 
pyrimidine hydrogens respectively, and around 8.1 for the C8 purine hydrogen. The only detectable 
protein in all samples was tmNrdD, both on the gel (Figure 12) and with MS (data not shown). The 
SDS-PAGE gel revealed that in the NrdD2 batch not only were the nucleotides were being broken 
down, but so was tmNrdD. This got worse over time for protein samples stored at 4°C (Figure 12). 
Because of the breakdown of both protein and nucleotides in NrdD2, and the NrdD1 batch being 
almost used up, the decision was made to purify more protein.  
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Figure 13 A: NMR spectra of 50 μM CTP. B: The same sample as in A after 2 h, showing no breakdown of nucleotide. 
C: B with 4 μM added tmNrdD. D: B with 8 μM added tmNrdD. E: B with 13 μM tmNrdD after 1 h. The nucleotide is 
stable until the addition of protein, when it slowly starts to degrade.  
 
 
 
 
 
Figure 12 Two SDS-PAGE gels showing the degradation 
of the NrdD2 batch over time. A: gel of NrdD2 after 
running NMR. B: samples of NrdD1 (lane 1) and NrdD2 
(lane 2) left in the fridge for several weeks. 
Figure 11 Three spectra from one NMR experiment: the top one 
contains 50 μM GTP, the middle one has added 4 μM NrdD and 
the final one has added 15 μM GTP. The change in shift is 
assumed to correspond to GDP, since this peak is present in 
NMR runs with GDP. The shift can not be explained by binding 
of GTP to tmNrdD, since 50 μM GTP should saturate 15 μM 
tmNrdD, thus some GTP should the left in solution.  
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Crystallisation and data collection 
Optimal crystallisation conditions for NrdD2 were 10-12% PEG3000, with a pH of about 5.7 for the 
native protein and slightly higher for co-crystallisation with nucleotides. For the newly produced 
batches the pH optimum was instead 5.9-6.1, with higher PEG3000 requirements of 16-17%. To 
obtain crystals of tmNrdD with bound nucleotides co-crystallisation was mainly used for NrdD2, 
while for the new batches soaking was mostly used. The crystals were visible after one day of 
growth and reached their maximum size after 2-3 days. Precipitation in the drops was common, 
with a lot of nucleation and microcrystals. When the protein was dialysed with MES buffer before 
crystallisation the results improved greatly, with significantly larger crystals more frequently 
(Figure 14). Setting up manual hanging drops, rather than use the pipetting robots at the MAX-lab 
crystallisation facility, also improved the size of the crystals.  
The crystals using protein in Tris buffer generally diffracted to about 3 Å, while the MES-
dialysed crystals diffracted to about 2 Å. No successful data sets with co-crystallised nucleotide 
could be obtained with the MES-dialysed protein, however these crystals diffracted well more often 
than those with protein in TRIS buffer. For crystals soaked with nucleotides the soaking needed to 
be carried out for at least 1 h for binding to occur. The data sets were generally anisotropic to 
varying degrees. The space group was always P21, with two different sets of unit cell parameters, 
seen below. For the smaller of these the b unit cell parameter was slightly more varied (Table 5). 
The smaller unit cell contained one dimer of tmNrdD and was known from before. The larger unit 
cell contained two dimers and had not been seen in previous work.  
 
    
               A B 
 
 
 
 
 
 
 
 
 
             C   D 
 
 
 
 
 
 
 
 
 
Figure 14 Representative crystallisation drops of good crystals before and after MES-dialysis. A 
and B are drops using protein in Tris buffer. C and D show crystals of MES-dialysed protein. The 
crystals in C are mostly flat triangles, with one of the sides facing upwards towards the top of the 
drop, making them look like rods. D is a drop set up with the robots at the MAX-lab 
crystallisation facility, but is also representative of good drops that were set up manually.  
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Table 5 Summary of the different types of crystal for which data collection was successful. No combination of effector 
and/or substrate is repeated in this table, for a more comprehensive list see appendix II. All NTPs are 2 mM, the dNTPs 
are 0.5 mM and all contain 10 mM Mg, unless otherwise stated.  
   
Unit cell parameters 
  
Effector Substrate Soak time a B c α β γ Resolution Notes 
- GTP 50min 79.5 92.5 87.3 90 112.7 90 2.2   
- ATP 2h 20min 77.6 93.2 86.5 90 112.2 90 2.6 0.2 mM ATP 
dTTP GDP 2h 55min 78.2 95 87.1 90 112.4 90 2.2   
dTTP ATP 2h 45min 79.9 99.5 88 90 112 90 2.1 
 
- ATP 2h 40min 78.1 98.1 87 90 111.9 90 1.8   
dGTP - 1h 77.9 93 86.6 90 112.7 90 2.8 
 
dCTP - 1h 5 min 77.7 92.5 86.8 90 112.4 90 2.3   
dATP - 1h 20 min 77.7 94.7 87.1 90 111.6 90 2.5 
 
dATP CTP 2h 45 min 78.1 95.5 87.3 90 111.8 90 2.5   
dTTP - - 77.4 87.1 86.1 90 112.1 90 3 
Zn anomalous, Mn 
used instead of Mg 
dTTP - - 78.1 93.7 86.8 90 112.2 90 2.8 
Mn anomalous, Mn 
used instead of Mg 
dTTP - - 77.6 87.2 86.4 90 112.1 90 3.4 
Fe anomalous, Mn 
used instead of Mg 
dGTP ATP 3h 15min 92.6 94.6 137.2 90 96.7 90 1.9   
dGTP ADP 3h 25min 93.7 95.5 138.6 90 96.9 90 1.9 
 
dGTP CTP 2h 45min 92.5 94.8 137.1 90 96.7 90 1.9   
dTTP GTP 1h 25 min 92 95.5 137.4 90 97 90 2 4 mM GTP 
 
Effector binding 
Crystal structures of all three effectors (dATP, dTTP and dGTP) bound to the effector site were 
obtained. The only successful effector binding achieved with NrdD1 was co-crystallised with dTTP. 
Soaking with dATP, dGTP and dCTP was attempted with the newer batches and successful datasets 
for dATP and dGTP effector binding were achieved in this way. dCTP, however, did not bind, 
regardless of soaking time. The phosphates of all effectors bound in the same positions, co-
ordinated by the Mg ion, Lys150, Thr154, Trp203, Gln207 and Gln210. Both the pyrimidine bases 
interacted with similar residues, while dTTP had fewer interactions. All three were co-ordinated by 
His158 and Glu147 (Figure 15). Loop 2 behaved as seen in previous work with tmNrdD: there was 
a clear conformational change when dATP was bound, with dTTP it resembled the native structure 
and with dGTP it was disordered (Aurelius 2011). 
 
dATP      dGTP     dTTP 
 
 
 
 
 
 
 
 
 
Figure 15 The tmNrdD effector site with the three different effectors bound: dATP, dGTP and dTTP. Lys150, thr154 
and trp203 that co-ordinate the phosphates, as well as a few side chains, have been omitted for clarity. The protein 
residues are shown as cyan lines, with the side chains in bold. The purple sphere represents the Mg.  
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ATP also bound the effector 
site, when crystals were soaked 
with it in the absence of dNTPs. 
The phosphates co-ordinated in 
the same way as the other 
effectors and the ribose inter-
acted with similar residues as 
for dATP (Figure 16). However, 
the ribose was shifted so that 
the 2´-OH took part in these 
interactions, while in dATP this 
hydroxyl group is missing and 
it is the 3´-OH that performs 
this role. In addition to this the 
ATP base was flipped com-
pared to dATP, resulting in 
different and less possible interactions. ATP binding did not seem to 
induce the same conformational changes as dATP, but remained very 
similar to the native and dTTP models (Figure 17).  
 
Metal characterisation 
The absorption edge scan for Zn showed a clear presence of a metal ion. 
In the same scan for Fe, however, it was not possible to detect any metal 
presence (Figure 20). An anomalous density map was generated for each 
dataset and in the case of Zn there was an anomalous signal at 30 σ in 
the expected location of the metal site at the optimal wavelength. No 
such peak could be seen in the anomalous density map for Fe. 
The absorption spectra for Mn gave a very clear signal for the 
presence of metal (Figure 19). The anomalous density map confirmed 
this by showing a very strong anomalous signal of 35 σ at the expected 
location of Mg binding, coordinating the three phosphates in the 
effector site. It confirms the expected Mg location in this protein 
(Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 19 Flourescence edge scan for Mn, at 1.89 Å. The lower spectra shows the  
            anomalous scattering factors: f´ (red) and f´ (blue).  
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B 
 
 
 
 
 
Figure 17 A: comparison of ATP 
(blue) and dATP (red) binding in 
the effector site. The ball by the 
phosphates represents the Mg. B: 
superposition of loop 2 when 
dATP (green), ATP (red) and dTTP 
(cyan) are bound. 
Figure 16 The tmNrdD effector site with bound ATP, 
shown in the same way as for the effectos in figure 15. 
Residues that interact with dATP have been included 
for comparison. 
Figure 18 dTTP bound in the effector 
site, showing how the Mn (purple 
sphere) co-ordinates the dTTP 
phosphates with the protein residues 
(grey). An anomalous density map at 
15 σ confirms the Mn location. 
(Figure from Oskar Aurelius) 
eV 
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Figure 20 Absorption edge scans for (A) Zn, at 1.28 Å, and (B) Fe, at 1.60 Å. The lower  
          spectra, for both A and B, show the derived anomalous scattering factors: f´ (red) and f´ (blue).  
 
Effector-substrate complexes  
Several structures of effector-substrate complexes 
were obtained, one of the first of these being dATP-
CTP. Here the electron density clearly shows binding 
of both effector and substrate. dATP binds in the 
same way as when no substrate is present, and CTP 
binding is consistent with previous RNR crystal 
structures with bound substrate (Larsson et al. 2004). 
The CTP phosphates form many interactions with 
residues 499-502, as well as Tyr112, His114 and 
Asp115. Two residues from loop 2: Arg221 and 
Gln224 reach in to the active site to interact with the 
CTP base, while the ribose is co-ordinated by Ser358 
(Figure 21).  
The only other effector-substrate complexes for 
which clear substrate binding has been achieved are 
those for dTTP-GTP and dTTP-GDP. Several 
structures have been obtained and in all cases the effector binds as expected, but the substrate has an 
orientation not seen previously. In these structures the substrate phosphates are shifted one step, so 
that the α and β phosphates of GTP and GDP are in the β and γ positions of the CTP phosphates in 
the dATP-CTP structure (Figure 23). Despite this both GTP and GDP phosphates still maintain the 
interactions with residues 499-502, as well as Tyr112, His114 and Asp115. The ribose is flipped, 
Figure 21 CTP substrate binding in the active site of tmNrdD. 
The protein residues are shown in cyan, with the side chains 
in bold. Some side chains have been omitted for clarity. 
eV 
keV 
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compared to CTP, and no longer interacts with ser358, but instead co-ordinates with Glu500, for 
GTP, and Tyr622, for GDP. It is instead the base, which has swung around, that interacts with 
Ser358 (Figure 22). This means the base is pointing in the wrong direction, as the hydroxyl groups 
of the ribose are now pointing away from the catalytically important residues (Figure 23). Neither 
GTP nor GDP interact with any of the residues from loop 2. 
 
GTP          GDP 
 
 
 
 
 
 
 
 
 
 
  Figure 22 Substrate binding of GTP and GDP in the active site of tmNrdD. The protein residues are  
         shown in cyan, with the side chains in bold. Some side chains have been omitted for clarity. 
The last of the expected effector-substrate combinations 
for which datasets were obtained were the dGTP-ATP and 
dGTP-ADP complexes. To investigate the possibility that, in 
contrast to other characterised RNRs, tmNrdD binds 
unexpected effector substrate combinations a dTTP-ATP 
dataset was also collec-ted. The effector bound in all three 
structures, but none of them showed clear substrate binding. 
However, in all cases a couple of blobs were visible in locations in the active site that corresponded 
to the positions of the β and γ phosphates of CTP (Figure 23). These same blobs were also visible in 
the ATP structure active site. The densities were very similar in shape to pyrophosphate, which were 
added to the structure and this generally improved the density, with only very marginal changes in 
R-factor. The interactions between protein and pyrophosphate were very similar to those seen for 
the corresponding phosphates in the structures with bound substrate (Figure 24). For the dTTP-ATP 
and ATP structures a third density blob was seen in roughly the same position as the CTP α 
phosphate, but it was not clear enough to insert anything into it (data not shown).  
The overall B-factors of the effector-substrate structures was around 30 Å
2
, with the exception of 
the dTTP-GTP structure where it was 14.5 Å
2
.  For both the effector phosphates and the α and β 
phosphates for the substrate (equivalent to β and γ in the CTP structure) the B-factor fluctuated in 
the region of 20-25 Å
2
. The exception was the dATP-CTP structure, where all bound phosphates 
had an average B-factor of 40 Å
2
. The GTP γ phosphate was in a position not overlapping with any 
other bound phosphate and here the B-factor was around 40 Å
2
. Appendix III contains a complete 
list of phosphate B-factors.  
A summary of effector-substrate binding can be seen in table 6.  
Figure 24 Representative pyrophosphate 
binding in the active site from the dGTP-ADP 
structure. The density is displayed around the 
pyrophosphate to 1.0 σ. The protein residues 
are cyan, with the side chains in bold. Some 
side chains have been omitted for clarity. 
   α 
 
         β 
         α 
 
   γ 
    β 
 
 
γ 
Figure 23 Superposition 
of the different 
molecules bound in the 
active site: CTP (blue), 
GTP (red), GDP (green) 
and pyrophosphate 
(yellow). The blue labels 
mark the different 
phosphates in CTP, 
while the red labels mark 
the phosphates in GTP. 
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Table 6 Overview of the best structures available for each effector and effector-substrate combination. dNTPs bind in 
the effector site and NTPs in the active site, unless otherwise stated. Entries in italics represent expected effector-
substrate pairs. Pyrophosphate has been shortened to pyrop.  
 ATP GTP CTP ADP GDP - 
dATP -  Both bound   Binds 
dCTP   -   Does not bind 
dGTP dGTP binds effector 
site, pyrop. in active 
site 
-  dGTP bound, 
pyrop. in ac-
tive site 
 Binds 
dTTP dTTP bound, pyrop. in 
active site 
Both bound   Both 
bound 
Binds 
- Binds effector site, 
pyrop. in active site 
     
 
 
 
Discussion 
Protein purification optimisation 
The presence of CAT (a chloramphenicol resistance gene encoded in the RIL plasmid of this E. coli 
strain) did not seem to be reduced by the absence of chloramphenicol. However, the initial batch, 
grown immediately after transformation with no intervening freezing step, was grown with only 
kanamycin present and when this batch was purified no CAT could be detected. For all subsequent 
batches the cells were initially grown on agar plates containing both kanamycin and 
chloramphenicol, and only the growth in liquid media was without this second antibiotic. This 
meant that CAT would be induced during the growth on agar plates, but for one and a half days 
there would be no chloramphenicol present, allowing the levels to drop. It could be possible, 
however, that the initial induction of this protein on the agar plates was enough to keep the bacteria 
producing CAT throughout growth. Another possible explanation is that the cultures with and 
without chloramphenicol were mixed up. But this is unlikely: there were 8 litres of culture for each 
type, which were kept separate from the addition of the antibiotic. A cell pellet from the cultures 
grown with both antibiotics from the same batch as those grown with only kanamycin has yet to be 
purified, which could possibly give shed light on if the cultures were mixed up.  
The last purified batch was homogenised by sonication, and here the yield improved by a factor 
of two compared to the previous batch. However, for every purified batch the yield has improved by 
a factor of two, due to continuous improvements to the protocol. Since only one pellet has so far 
been purified with sonication it is not possible to determine absolutely whether sonication 
significantly improves the yield. For the pellet homogenised with sonication there were two major 
differences compared to the previous ones: there was no presence of chloramphenicol in the liquid 
growth media and it was sonicated instead of run through the French press. The lack of 
chloramphenicol did not seem do decrease CAT levels, as discussed above, suggesting that this 
change in conditions did not significantly affect the cells, and as such probably would not have 
contributed to the increased protein yield to such an extent. Anther thing that speaks for this is that 
the amount of harvested cells did not increase when chloramphenicol was removed. Thus it can be 
assumed that sonication improves the protein yield in comparison to the French press. Further 
purifications should the done to verify this.  
It was clear from the SDS-PAGE gels that decreasing the time of the heat precipitation step 
decreased the loss of tmNrdD. Since the protein originates from bacteria with an optimal growth 
temperature of 80°C it might be considered logical that it should not matter if the time spent at 75°C 
is 20 min or 5 min. However, in its native state the protein makes a complex with its activase NrdG, 
which might help stabilise the structure at higher temperatures. Under normal circumstances the 
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protein would be turned over regularly, replacing damaged ones. It is also very likely that the T. 
maritima cells have other mechanisms in place to increase protein stability. E. coli would lack most 
of these functions, which would in any case probably not be functional in the semi-purified protein 
mixture that tmNrdD is in during heat precipitation. All of these factors would increase heat 
sensitivity, meaning that even tmNrdD would be affected by the duration of this purification step.  
Of the three pellets from purification the homogenisation pellet was the smallest. This is a good 
sign, since it means that most of the cells are broken up, and that there is little large debris. That the 
heat precipitation pellet is the largest is also positive: a large portion of the contaminating proteins 
is removed at this stage, since most proteins in E. coli aggregate out of solution at such high 
temperatures. The weight of the ammonium sulphate precipitation pellet does not correlate with the 
protein yield, which is not surprising as the final protein yield is only a small fraction of that pellet’s 
total weight. This clearly demonstrates the need for further purification.  
Two of the butyl Sepharose column peaks contained tmNrdD. That there are two different elution 
profiles is possible: if some the protein had bound nucleotide during purification its hydrophobicity 
might be different from the native protein, causing it to elute at a different time, happening to 
coincide with the elution of CAT.  
The final protein yield of the last batch of purification was sufficient for crystallisation, since 
purification from only a few litres of culture would last for more than one month. However, it was 
still much lower than for Etienne, who had final protein yields of about 15 mg/l culture, using the 
same protocol he sent for purification of the newer batches. This was the reason the protocol was 
optimised, to determine what possible differences could have been introduced that caused the yield 
to be so much lower. The only major change done to the protocol when it was sent was the use of 
French press instead of sonication. Changing this back seemed to improve the yield, as discussed 
above, but the yield, even in the final batch was still about 3-4 times lower than expected. The 
increase in protein yield observed for the newer batches could have several causes, one of the major 
ones being more practiced handling and building up a routine for working with the protocol. For 
that reason it is possible that new batches produced with have further increased yield, however it is 
unlikely that this reason alone would bridge such a large difference. Other differences could be 
variations in the chemicals used for media and buffers, or different efficiencies of the columns, but 
again this probably does not account for this large gap. Further investigation and purification of new 
batches are necessary to solve this problem.  
 
NMR and MS 
The breakdown of both nucleotides and tmNrdD in NrdD2 was batch-dependent and not seen in 
NrdD1, strongly indicating the presence of one or more contaminating proteins. The concentration 
of these contaminants would be very low, since they could not be detected with either SDS-PAGE 
or MS. Another thing that speaks for this is the very slow rate at which breakdown occurred: for the 
nucleotides it could only be observed over several hours and even after weeks in the fridge there 
was still full length tmNrdD visible on the SDS-PAGE gel. That dTTP was not degraded could be 
used as a clue as to what protein or proteins was causing the degradation. However, since this 
degradation was batch dependent the decision was taken to produce our own protein and stop using 
NrdD2, rather than investigate the cause further.  
 
Crystallisation and data collection 
There was a small increase in optimal crystallisation pH for the new batches, but dialysis with MES 
producing so much better overall results, both in crystal appearance and data collection, might 
actually be a step in the other direction. Before dialysis the protein was kept in Tris buffer, pH 8, 
and after dialysis in MES pH 7.5. The main difference here is that Tris buffers at a higher pH than 
MES (Dawson et al. 1986). The drops were 50% reservoir with 100 mM MES and 50% protein 
solution with 50 mM Tris or MES, meaning this would have had some effect on the final pH of the 
drops. The change would not have been drastic, but the final pH for MES dialysed protein would 
probably have been significantly lower, resulting in an overall drop in optimal crystallisation pH.  
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Soaking also improved the results of data collection for the new batches, compared to co-
crystallisation. If this was consistent is hard to say, however, since only one co-crystallisation screen 
was performed. Also, most of the crystals later screened at MAX-lab for soaking experiments were 
dialysed with MES, while the co-crystallisation screen was not.  
 
Effector sites 
dCTP binding has been seen in the effector site of the BT4 class III RNR, but could not be observed 
in this case (Larsson et al. 2001). It is, however, possible that lack of binding was due to suboptimal 
conditions or too short soaking time. That soaking generally needs a long time for binding to occur 
can be explained, both by the crystal packing and by being in a solution so far from in vivo 
conditions. The crystal is not a rigid structure, but its highly ordered nature can make it harder for 
the nucleotides to reach the effector or substrate sites. Though the solution the protein is in is 
favourable for maintaining the integrity of the crystal, in the case of the cryo solution where the 
nucleotides are introduced these conditions might not be favourable for nucleotide binding, which 
would also increase the time required.  
The dATP, dGTP and dTTP interactions with the residues in the effector site is similar to what 
has been seen in previous work on tmNrdD (Aurelius 2011). There are, however, several differences 
to the effector binding in BT4 (Larsson et al. 2001). Firstly, although the phosphates are co-
ordinated by a Mg ion in both cases, this metal in turn interacts differently with the effector site. In 
tmNrdD this role is performed by two glutamines that also interact directly with the phosphates. In 
the BT4 class III RNR it is instead a water molecule that co-ordinates the Mg, bridging a larger 
distance to Gln100 and Lys103 (BT4 class III numbering). This increase in distance allows Gln100 
to co-ordinate the hydroxyl group on the deoxyribose as well, an interaction not seen in any effector 
complexes for tmNrdD. Here the hydroxyl group instead points in the other direction, though it still 
interacts with the backbone N of a glutamine (Gln147, tmNrdD numbering), the same type of inter-
action as seen in BT4. The hydrogen bonding of the base is different both with regards to the 
residues involved and which atoms on the base that participate. In BT4 there are two key residues in 
effector base binding, while in tmNrdD there are two for dTTP and 4-5 for the purimidines. Though 
one of the key residues for loop 2 conformational changes is indeed a glutamine in tmNrdD this 
only interacts with dTTP, while in BT4 Gln114 interacts with everything except dGTP. The way 
loop 2 changes in response to various effectors is also different. Interestingly, the effectors that 
cause the largest and smallest conformational changes in tmNrdD (dATP and dTTP respectively) are 
the opposite in BT4.  
That ATP binds the effector site has previously been seen in BT4 (Larsson et al. 2001). It is 
possible that also GTP may be able to bind the effector site, but no such structures have yet been 
solved, so this remains to be investigated. There is less interaction between ATP and the effector 
site, compared to dATP, indicating a weaker binding and probably lower affinity. Because ATP does 
not seem to change the conformation of loop 2 it is unlikely that it contributes to CTP binding in the 
active site, but could possibly induce binding of another substrate. One candidate would be GTP, 
which already binds when the loop 2 conformation is similar to the native structure. In other RNRs 
ATP modulates overall activity, where it binds to the ATP cone (Nordlund and Reichard 2006), but 
in class III RNRs that lack the activity cone there is no overall activity regulation, meaning that 
could not be a possible function for this binding. Overall, further studies are needed to confirm the 
role of ATP in the effector site, as many questions are still unanswered.   
 
Metal characterisation 
The absorption edge spectra and anomalous signal for Zn indicated that this was the metal present 
in the metal site on the protein. However, Fe can also give an anomalous signal at the wavelengths 
for Zn, meaning this result alone would not be conclusive. But since there was no presence detected 
on the absorption edge scan or the anomalous density map for Fe, this is a strong indicator that the 
metal site actually contains Zn.  
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The Mn co-ordinates the three phosphates of the effector with Glu207 and Glu210 in the effector 
site, as expected. Interestingly, though modelling in tmNrdD has always been done with Mg at this 
location, for the class III RNR from BT4 the Mg and β-phosphate are in swapped positions (Larsson 
et al. 2001).  
 
Effector-substrate complexes 
The dATP-CTP complex shows clear binding of both substrate and effector in accordance with pre-
vious literature (Larsson et al. 2004) and is the first time that such a complex has been achieved for 
a class III RNR. For the dTTP-GTP or dTTP-GDP structures, however, the phosphates have shifted 
one step, the ribose has flipped and the base is pointing in the wrong direction. For all other at-
tempted effector-substrate complexes the only thing visible in the active site is a pyrophosphate. 
The one thing that was consistent throughout all substrate binding was the position of two of the 
phosphates (β and γ for CTP), which all interacted with the same protein residues. This site is high-
ly electrophilic, causing binding to negatively charged molecules, such as phosphates. This has been 
seen in previous work where the buffer has bound to this highly electrophilic site, blocking any at-
tempts at substrate binding (Larsson et al. 2001; Aurelius 2011).  
GTP and GDP are in conformations not seen before, indicating two options: the protein is not ac-
tive, or it is an artefact. This conformation could indicate and inactive protein because the ribose is 
pointing away from the catalytically important residues responsible for reduction of the 3´OH. 
Since there are several datasets with solved structures for this effector substrate combination where 
the substrate is oriented in the same way (see appendix II), the likelihood that it is an artefact de-
creases. If the protein would be active with the substrate in this conformation the reaction pathway 
would have to take a different route than what is commonly known. One such option would be that 
Tyr227 would swing round to the ribose, acting as a shuttle. However, this is less likely since 
Tyr227 is thought to contribute to maintaining the active site structure. As such, it is inconclusive 
what significance this new conformation of GTP and GDP has.  
The only other visible active site binding was of pyrophosphates in the various structures with 
ATP or ADP. One possibility was that these densities belonged to phosphates from broken down 
nucleotides. There did not seem to be such an issue with other substrates binding, such as GTP or 
CTP, although it could be that only ATP and ADP was being affected. The likelihood of that 
decreases, however, since the ATP effector site density was very clear, yet there were still only a 
few blobs in the active site. It is possible that the strongly hydrophilic active site region is more 
sensitive to degradation products and more prone to bind them than the effector site, but overall 
these things speak for nucleotide degradation being possible, but unlikely.  
Another possible explanation for the pyrophosphates in the active site was that the protein, being 
crystallised in its inactive state, would have relatively poor substrate binding. If this was the case, 
the substrate might still bind, but very transiently. The hydrophilic site around the phosphates would 
bind much more tightly than the rest of the molecule, something that is supported by all substrate 
structures having phosphates in those two positions, regardless of what positions the other parts of 
the molecules were in. This would mean that the phosphates would bind tightly enough to be visible 
in the electron density, but the rest of the molecule might be so mobile that it would not. It is also 
possible that ATP and ADP are more mobile in the active site than CTP or GTP/GDP, which would 
explain why it is not possible to see their densities. CTP co-ordinates with residues from loop 2, 
meaning it probably has more stable binding than the large purines, which do not. Similarly, the 
GTP and GDP conformations seen might be most stably bound in the current state of the protein, 
but they might adopt different ones in the active protein. Something that speaks for this is that 
several interactions are visible between the base and protein in the current structures, which in both 
cases involve the hydroxyl group missing in ATP. As such, it is possible that ATP also binds in that 
conformation, but since there is less to interact with it is less stable. Consequently their con-
formation does not have to indicate an inactive protein and there might be more substrate binding 
than is currently possible to visualise.  
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There was little variance B-factors of phosphates bound in the same position in the effector and 
active sites. The exception was the dATP-CTP structure, where the phosphate values were about 
twice as high. The dataset for this structure was to a lower resolution and of worse quality than most 
of the others, which explains the higher values. The overall B-factors can not be compared, since 
some of them are residual B-factors, while others are total B-factors and it is not possible to relate 
them to each other. When determining the optimal positions of the phosphates, it might have been 
possible to use the comparison of B-factors of phosphates in the different positions to support the 
hypothesis discussed above about a mobile substrate. In that case the two phosphate sites where it is 
possible to see a pyrophosphate should have considerably lower B-factors than the third phosphate 
position. However, this is only the case in the dTTP-GTP structure, while in the dATP-CTP struc-
ture it is not. Because only two structures with three phosphates in the active site are available it is 
not possible to determine if the differences in B-factors between phosphates support the discussion 
regarding a mobile substrate. To determine this more structures with bound triphosphates in the ac-
tive site would be necessary.  
 
 
 
Conclusions 
Protein production of tmNrdD was generally successful with a final protein yield of about 4 mg/l 
culture. However, the protocol still needs optimisation and further work to increase the protein yield 
up to the levels achieved by Etienne. Crystallisation in MES buffer, and especially dialysis of the 
protein solution to remove Tris buffer, greatly improved crystallisation and data collection results. 
The metal site in tmNrdD has been confirmed to contain Zn, and the location of the Mg coordinat-
ing the phosphates in the effector site has also been determined.  
Structures for all known specificity effectors have been obtained, as well as three substrate effec-
tor complexes. Though the dATP-CTP complex binds according to previously known data, the 
dTTP-GTP complex does not, with the substrate in a previously undetected conformation. In at-
tempted structures with dGTP-ATP it was only possible to detect pyrophosphates in the active site. 
It is possible this is due to a larger flexibility in the substrate while the protein is inactive, than pre-
viously thought. Further work needs to be done to determine protein activity, and to attempt to ob-
tain effectors substrate complexes with ATP, to shed light on these interesting developments.  
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Appendix I: Purification protocol for production of tmNrdD (adapted from Etienne Mulliez) 
 
Production using 1 litre cultures.  
 
Materials 
 Sterile pipette tips and Eppendorf tubes 
 Clones: 
◦  pRSFduet-1 with NrdD in BL21-(DE)-RIL in glycerol stock, kept at -80ºC 
 0.5 l LB-agar: 
◦  5 g Tryptone 
◦  2.5 g yeast extract 
◦  5 g NaCl 
◦  7.5 g agar 
◦  Before pouring into Petri dishes: 
▪  500 μl 30 mg/ml kanamycin 
▪  500 μl 100mg/ml chloramphenicol 
 (1 l LB-media)*x: 
◦  10 g NaCl 
◦  5 g yeast extract 
◦  10 g Tryptone 
 Stocks:  
◦  10 ml kanamycin 30 mg/ml (400 mg of 0.75 mg/mg in 10 ml water) 
◦  10 ml chloramphenicol 100 mg/ml (1 g in 10 ml water)  
◦  10 ml 250 mM IPTG 
◦  10 ml 150 mM Zn2+ 
◦  10 ml DTT 1M, frozen as 1 ml aliquots, made previously 
◦  100 ml 250 mM Tris, 1.25 M KCl pH8 
▪  3.028 g Tris 
▪  9.32 g KCl 
▪  Fill up to 80 ml ddH2O 
▪  Adjust pH 
▪  Top up to 100 ml 
◦  300 ml 500 mM Tris 500 mM KCl pH8 
▪  18.16 g TRIS 
▪  11.184 g KCl 
▪  Fill up to 280 ml ddH2O 
▪  Adjust pH 
▪  Top up to 300 ml 
 100 ml lysis buffer: 
◦  50 mM Tris, 250 mM KCl (20 ml 250 mM TRIS, 1.25 M KCl pH8) 
◦  200 μM PMSF (3.48 mg) 
◦  5 mM DTT (0.5 ml 1M) 
◦  Up to 100 ml with ddH2O 
 500 ml Buffer 1: 
◦  1 M Ammonium sulphate (63.41 g) 
◦  50 mM Tris, 50 mM KCl pH 8 (50 ml 500 mM pH 8) 
◦  Fill up to 500 ml with ddH2O 
◦  Filter and degas the finished buffer 
 300 ml Buffer 2: 
◦  50 mM TRIS, 50 mM KCl pH8 (30 ml 500 mM pH8) 
◦  Fill up to 300 ml with ddH2O 
◦  Filter and degas the finished buffer 
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 400 ml Buffer 3: 
◦  50 mM Tris, 50 mM KCl pH8 (40 ml from stock) 
◦  5 mM DTT (2 ml from stock) 
◦  Fill up to 400 ml with ddH2O. 
◦  Filter and degas the finished buffer.  
 
Unless otherwise stated keep everything on ice AT ALL TIMES. 
 
Day 1 
Scrape some cells off from the glycerol stock and streak on an agar plate, containing kanamycin 
(30 μg/ml) and chloramphenicol (100 μg/ml). 
Incubate at 37ºC over night.  
 
Day 2 
Clean-streak single colonies on to kanamycin + chloramphenicol agar plates.  
Incubate at 37ºC over night.  
 
Day 3 
Innoculation 
To 50 ml tubes with 10 ml LB-media per 1 litre culture intended add: 
 10 μl Kanamycin stock 
 10 μl Chloramphenicol stock 
 10 μl Zn2+ stock 
Innoculate a single colony of NrdD into each of the tubes. 
Incubate overnight on a shaking table at 37ºC, 200 rpm. 
 
Day 4  
Growth and expression 
To baffled flasks containing 1 l LB-media add: 
 1 ml Kanamycin stock 
 1 ml Chloramphenicol stock 
 1 ml Zn
2+
 stock 
 10 ml overnight culture of NrdD 
Incubate at 37ºC, 200 rpm. Measure OD600 every hour until it reaches 0.3-0.4, then more 
frequently until 0.5-0.7. This takes about 3 hours. 
Freeze 1 ml of each culture. 
Add 1 ml IPTG stock to each flask and incubate for 3 hours at 37ºC, 200 rpm.  
After 1 h 30 min:  
 Remove 1 ml of each culture and measure OD600.  
 Normalise the volume for each sample, including those aliquots removed previously, using 
 200 μl of the one with the highest OD.  
 Centrifuge and resuspend the pellets in 30 μl H2O.  
Use the resuspentions to run a gel, to see if there is expression. When preparing for the gel 
incubate at 90ºC and dilute liberally, since this becomes very viscous.  
After the 3 hour incubation centrifuge the cultures at 6000 rpm, 12 minutes 
Discard the supernatant. 
Weigh the pellets. 
Freeze and store the pellets at -80ºC. 
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Day 5 
Homogenisation 
Dissolve the cell pellets in 20-30 ml lysis buffer. (About 4 volumes, v/w) 
Lysate 15-20 ml at a time using sonication: 80 W, 6 cycles of 20 s pulses with 60 s rest. 
Centrifuge for 20 min at 20 000 g. 
Pool the pellets, weigh and save as P1 at -20ºC, save a knife’s edge separately for running a gel. 
Incubate the supernatant at 75ºC for 5 min.  
Centrifuge for 10 min at 10 000 g. 
Weigh and save the pellet as P2 at -20ºC, save a knife's edge separately for running a gel. 
Slowly saturate the supernatant with ground ammonium sulphate, up to 60% (390 g/l) during 
very careful stirring.  
Leave on a sample wheel on the slowest possible speed for 10 min.  
Centrifuge for 10 min at 10 000 g.  
Save the supernatant as S1 at -20ºC, after running the gel mentioned below.  
Weigh the pellet, save a knife's edge separately for running a gel and store the rest at -20ºC as P3 
for use the next day. 
Run an SDS-PAGE gel. To normalise the small pieces of pellet to the supernatant S1 and ensure 
similar conditions dissolve the pellet in ddH2O according to the following formula: 
 
(Assumed total V of supernatant * Weight of pellet fraction)/(Total pellet weight) = Volume of 
water to dissolve the pellet in 
  
      1          2          3      4   5 
  
                 170 kDa 
                 130 kDa 
                 100 kDa 
                   70 kDa 
 
                   55 kDa 
           40 kDa 
         
                   35 kDa 
                   25 kDa 
 
           15 kDa 
 
           10 kDa 
 
SDS-PAGE gel of the collected pellets and supernatants. Lane 1: P1, lane 2: P2, lane 3: P3,  
 lane 4: S1 and lane 5: ladder.  
 
Day 6 
Purification: butyl sepharose high trap column  
Equilibrate a butyl Sepharose Fast Flow HiTrap column (5 ml, GE Healthcare) with 50 ml buffer 
1. If the pressure allows, keep the flow up to 5 ml/min throughout.  
Thaw P3 from day 5 and dissolve in 4 ml buffer 1. 
Measure the protein and nucleotide concentrations. 
Centrifuge for 10 min at 10 000g.  
Load the column with the total amount of protein from up to two litres of bacterial culture.  
Elute with 0-100% buffer 2, mixed with buffer 1, collecting 1 ml fractions over 100 ml.  
There are two fractions at the end of the gradient that both contain tmNrdD. The latter one also 
contains chloramphenicol acetyl transferase and should be discarded. Pool the fractions of the first 
of these peaks.  
Wash the column with 25 ml buffer 1. 
Load more protein if necessary, repeating the last three steps.  
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When all protein has been run through, wash with 50 ml ddH2O, then with 20% EtOH. 
Pool all the collected fractions and measure the concentration.  
Fill two Falcon tubes with 15 ml concentration filters for 10 kDa with buffer 2 and centrifuge at 
8000 rpm until all liquid is run through to wash them.  
Concentrate the protein using the two tubes. 
Add 100 μl DTT to 20 ml buffer 2. Add 10 ml of this to each of the concentrated protein tubes 
and concentrate again down to about 0.25 ml. 
Measure the concentration again. 
Transfer to an Eppendorf Tube, using the largest possible pipette tip, and washing the walls. 
Store in the fridge over night. 
 
Day 7 
Equilibrate a Superdex 200 column (23 ml) with 50 ml ddH2O, then 50 ml buffer 3 at 0.5 
ml/min. This can be done over night.  
Load the protein, no more than 10 mg protein or 0.3 ml sample.  
Elute with 30 ml buffer 3.  
TmNrdD appears as a large peak at about 10 ml. Collect 0.25 ml fractions in this area and pool 
them. 
If necessary reload the column until all the protein has been run through.  
Measure the concentration of all the pooled fractions. 
Concentrate using 0.5 ml concentration tubes for 30 kDa, centrifuged at 8000g. Measure the 
concentration using nanodrop and, if necessary, dilute the protein samples to a final concentration of 
20-25 mg/ml.  
Run DLS and an SDS-PAGE gel.  
Aliquot the protein in to 20-30 μl fractions.  
Flash freeze in liquid nitrogen and store at -80ºC.  
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Appendix II: Comprehensive overview of the different crystals tested for data collection 
Date Effector Substrate Soak time 
Data 
set 
Space group 
parameters 
Reso-
lution 
R-
factor 
R-free Notes 
130421 - GTP 8h 40min N 
  
  More than one crystal. 25% PEG400 
130421 - GTP 8h 40min Y 
 
2,8   
Xds couldn't index. Didn't finish col-
lecting. 25% PEG400 
130421 - GTP 9h 30min N 
  
  25% PEG400 
130421 - ADP 10h Y 
  
  
Xds couldn't index. Didn't finish col-
lecting. 25% PEG400 
130421 - ATP 10h 30min Y 
  
  
Xds couldn't index, didn't finish 
colletcing. 25% PEG400 
130421 - ATP 45min N 
  
  ATP at 0.2 mM (1/10th normal conc) 
130421 - GTP 50min Y 
79.5  92.5  87.3  
90.0  112.7  90.0 
2,2 0.405 0.496 Nothing bound 
130421 - ATP 2h 20min Y 
77.6   93.2   86.5  
90.0 112.2  90.0 
2.6 0.362 0.437 ATP at 0.2 mM (1/10th normal conc).  
130418 dGTP ATP 3h 5min Y 
78.6   95.0   87.3  
90.0 112.0  90.0 
2,1   
2 crystals, some ice. dGTP bound, 2 
blobs in active site 
130418 dGTP ADP 3h N 
  
  Very split 
130418 dGTP ADP 2h 55min N 
  
  Just ice 
130418 dGTP ADP 4d N 
  
  Lots of ice 
130418 dTTP GDP 2h 55min Y 
 
2,2   Slightly split. Both bind fine 
130418 dGTP ATP 4 d N 
  
  Lots of ice 
130418 dGTP ATP 3h 15min Y 
92.6   94.6  137.2  
90.0  96.7  90.0 
1,9 0.250 0.306 
More than one crystal in the loop. 
dGTP binds clearly. Two larger blobs 
in active site 
130418 dTTP ATP 2h 45min N 
  
  No crystal, just some ice on the edge 
130418 dTTP ATP 2h 45min Y 
79.9  99.5  88.0  
89.7  112.0  90.8 
2,1 0.206 0.257 
A bit cracked. Very clear density for 
dTTP, and for 3 blobs in active site 
130418 - GDP 2h 45min N 
  
  Just ice 
130418 - GDP 2h 45min N 
  
  Just ice 
130418 - GDP 4 d N 
  
  Just ice 
130418 - ADP 2h 45min Y 
  
  
A bit split, but ok. Not solvable by 
xds 
130418 dGTP ADP 3h 25min Y 
93.7   95.5  138.6  
90.3  96.9  89.7 
1,9 0.244 0.290 
A little bit split. Not very anisotropic. 
dGTP bound, two blobs in active site 
130418 - ATP 2h 40min Y 
78.1  98.1  87.0  
90.0  111.9  90.0 
1,8 0.217 0.257 
No splitting. Binds effector site clear-
ly, 3 blobs in active site 
130418 dGTP CTP 2h 45min Y 
92.5   94.8  137.1  
90.0  96.7  90.1 
1,9 0.491 0.541   
130418 - ADP 2h 45min Y 
  
  
Didn't finish: the crystal wasn't great 
and because of no injection the inten-
sity was very low.  
130317 dATP - - N 
  
  8 crystals tested  
130317 - - - N 
  
  5 crystals tested 
130317 dATP - 30 s Y 
 
3   Not bound, not long enough soaking 
130317 dATP - 1 h Y 
78.1   93.4   86.8  
90.0 112.3  90.0 
2,9   Bound 
130317 dGTP - 5 min Y 
 
3,1   Not bound, not long enough soaking 
130317 dGTP - 1h Y 
77.9   93.0   86.6  
90.0 112.7  90.0 
2,8 0.356 0.446 Both effectors bind, relatively clearly 
130317 dCTP - 50 min N 
 
3     
130317 dCTP - 1 h N 
 
2,7   Very split 
130317 dCTP - 1h 5 min Y 
77.7   92.5   86.8  
90.0 112.4  90.0 
2,3   Lots of ice. No binding 
130317 dCTP - 3h 15 min N 
  
    
130317 dCTP - 3h 30 min N 
  
  Very split 
130317 dCTP - 3h 40 min Y 
77.7   93.6   86.6  
90.0 112.3  90.0 
2,5   No binding 
130317 dATP - 1h 20 min Y 
77.7   94.7   87.1  
90.0 111.6  90.0 
2,5 0.351 0.448 
Both effector sites have dATP bound, 
one of the clearer than the other.  
130317 dTTP GTP 2h 30 min Y 
77.9   97.8   86.7  
90.0 111.9  90.0 
2,3   Some ice rings. Both bind 
130317 dGTP ATP 1h 10 min N 
 
2,2   Very split 
130317 dTTP 2xGTP 1h 25 min Y 
92.0   95.5  137.4  
90.0  97.0  90.0 
2 0.194 0.269 Both bind 
130317 dATP CTP 2h 30 min N 
 
3     
130317 dATP CTP 2h 45 min Y 
78.1   95.5   87.3  
90.0 111.8  90.0 
2,5 0.214 0.256 Snow. Nice binding 
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130224 dTTP - - Y 
  
  
Zn anomalous, Mn used instead of 
Mg. 3 datasets 
130224 dTTP - - Y 
  
  
Mn anomalous, Mn used instead of 
Mg. 5 datasets 
130207 dTTP - - Y 
  
  
Anomalous data sets for Fe, Zn and 
Mn. Cocrystallised with Mn, not Mg 
130207 dGTP - 5min N 
  
  Ice rings 
130207 dGTP - 3min N 
  
  Some ice rings 
130207 dGTP - 1min N 
  
  Nothing 
130207 dGTP - 1min N 
  
  Nothing 
130207 dGTP - 3min N 
  
  No cryo, ice 
130207 dGTP - 5min N 
  
  
dGTP soaked in drop, then transferred 
to cryo, then frozen. 
130207 dTTP - - N 
  
  
Crystallised with Mn instread of Mg. 
4 datasets 
130125 dTTP - - Y 
  
  
Zn & Fe anomalous datasets, Mn 
used instead of Mg 
121104 dTTP - - N 
  
  2 crystals tested 
121104 - - - N 
  
    
121104 dGTP - - N 
  
  3 crystals tested  
121104 dATP - - N/Y 
  
  2 crystals tested, 1 dataset 
121104 dCTP - - N 
  
  2 crystals tested 
121019 - - - N/Y 
  
  6 crystals tested, 1 dataset 
121019 dTTP GDP - Y 
  
    
121019 dATP - - N 
  
    
121019 dCTP - - N/Y 
  
  2 crystals tested, 1 dataset 
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Appendix III: B-factors of phosphates in the effector and active sites 
 
The phosphate B-factor values are organised so that corresponding positions in the structure are in 
the same column. For this reason the substrate phosphate positions in brackets indicate the GTP 
phosphates. The mean B value is for the whole protein. 
 
Effectors Substrates   
 
α β γ α β (α) γ (β) γ Mean B value 
ATP* 
19.7 24.3 24.3   26.4 17.3   
26.4 
18.8 25.1 24.5   21.0 30.5   
dATP-CTP 
41.4 39.0 48.7 39.7 40.5 38.1   
31.0 
38.7 48.0 42.8 43.8 41.8 34.3   
dGTP-
ADP* 
20.6 19.3 26.3   32.7 24.9   
30.0 
21.2 22.8 28.3   38.2 27.7   
19.3 23.3 26.0   30.6 24.2   
20.4 22.9 26.7   27.4 31.5   
dGTP-
ATP* 
27.4 33.6 42.0   18.4 24.0   
28.5 
35.9 32.4 34.7   24.8 21.2   
22.6 24.7 29.8   21.3 16.8   
23.3 23.8 21.7   18.2 19.4   
dTTP-ATP* 
19.8 22.3 22.0   21.2 29.4   
29.4 
25.3 20.3 20.5   28.8 18.7   
dTTP-GDP 
20.3 25.2 26.8   22.1 16.9   
30.5 
23.3 28.3 27.5   23.4 19.0   
dTTP-GTP 
17.9 19.7 22.2   20.9 20.4 45.5 
14.2 
15.8 18.7 19.5   27.6 20.2 43.2 
16.7 17.0 18.6   24.2 19.5 51.5 
14.8 15.6 18.2   26.3 20.4 53.8 
* = the active site of this complex only contains pyrophosphate 
